Our UHN programs and services are among the most advanced in the world. We have grouped our physicians, staff, services and resources into 10 medical programs to meet the needs of our patients and help us make the most of our resources.
University Health Network is a health care and medical research organization in Toronto, Ontario, Canada. The scope of research and complexity of cases at UHN has made us a national and international source for discovery, education and patient care.
Our 10 medical programs are spread across eight hospital sites – Princess Margaret, Toronto General, Toronto Rehab’s five sites, Toronto Western – as well as our education programs through the Michener Institute of Education at UHN. Learn more about the services, programs and amenities offered at each location.
Maps & Directions
Find out how to get to and around our nine locations — floor plans, parking, public transit, accessibility services, and shuttle information.
Ways You Can Help
Being touched by illness affects us in different ways. Many people want to give back to the community and help others. At UHN, we welcome your contribution and offer different ways you can help so you can find one that suits you.
The Newsroom is the source for media looking for information about UHN or trying to connect with one of our experts for an interview. It’s also the place to find UHN media policies and catch up on our news stories, videos, media releases, podcasts and more.
Five UHN Researchers – Drs. Beate Sander, Myron Cybulsky, Jordan Feld, Andrea Iaboni and Patrick Lawler – have been awarded funding from the Government of Ontario for COVID-19 research.
The Ontario COVID-19 Rapid Research Fund was launched in April to generate rapid solutions to fight the disease. The following funded projects will tackle ongoing challenges in screening and treatment of the disease, planning of healthcare resources, and management of long-term care homes.
Ontario's Response to COVID-19: Balancing Trade-offs and Improving Outcomes for all OntariansDr. Beate Sander, Scientist at Toronto General Hospital Research Institute Dr. Sander's team has developed the COvid19 Resource Estimator (CORE) model to support capacity planning and public health interventions. The model will be expanded to forecast COVID-19 case numbers and examine their effect on the acute care system and health outcomes for Ontarians. By examining a range of reopening scenarios, this research will help the province to plan mitigation strategies that balance healthcare system capacity, population health and broader societal outcomes, such as economic impact.
Development and Validation of Flexible Medium Throughput Solutions for COVID-19 DiagnosticsDr. Myron Cybulsky, Senior Scientist at Toronto General Hospital Research Institute As workplaces reopen, extensive screening of COVID-19 will be vital to identify asymptomatic and presymptomatic individuals. Dr. Cybulsky's team will evaluate various methods of diagnosing COVID-19 that are adaptable to nasal swab, saliva and saline gargle testing. They will then develop tests based on rigorous clinical standards. The development of different diagnostic tests will help the province to manage outbreaks and shortages in test reagents while providing rapid and cost-effective testing strategies.
Interferon Lambda for Immediate Antiviral Therapy at Diagnosis (ILIAD): A Phase II Randomized, Open-label, Multicentre Trial to Evaluate the Effect of Peginterferon Lambda for the Treatment of COVID-19Dr. Jordan Feld, Senior Scientist at Toronto General Hospital Research Institute Dr. Feld will evaluate the drug peginterferon-lambda in ambulatory and hospitalized patients with mild to moderate cases of COVID-19. Peginterferon-lambda has been extensively studied and has been used to treat other viral diseases, such as hepatitis B and C. The trial will determine whether the drug improves the ability of individuals to clear the SARS-CoV-2 virus.
Toolkit to Prevent COVID-19 Transmission among Persons with Dementia in Long-Term CareDr. Andrea Iaboni, Senior Scientist at KITE Research Institute Dr. Iaboni's team will develop, implement and evaluate a Dementia Isolation Toolkit for long-term care homes. A series of methods and approaches will be designed to support the compassionate, safe and effective isolation of individuals with dementia without compromising their dignity and personhood. The toolkit will help improve the implementation of infection control protocols in long-term care homes, reduce community spread of the virus and protect healthcare workers. The team will support the implementation of the toolkit through ongoing evaluation and consultation.
The Antithrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC) Trial: A Multinational Randomized, Adaptive, Controlled Clinical Trial – Support for Personnel at the International Clinical Coordinating Centre in OntarioDr. Patrick Lawler, Scientist at Toronto General Hospital Research Institute
Dr. Ewan Goligher, Scientist at Toronto General Hospital Research Institute In partnership with Dr. Ryan Zarychanski (University of Manitoba) and researchers from Canada, the United States, Brazil and Mexico, Drs. Lawler and Goligher will test a blood thinner called heparin for its effectiveness in treating severe COVID-19 infection. Heparin may also have anti-viral and anti-inflammatory effects, and has the potential to reduce mortality and the need for mechanical ventilation in hospitalized patients.
Read more about the Ontario government funding announcement